marcus evans europe conferences

Translating Innovations in Diabetes Drug Development

Fostering Innovative Clinical Efforts to Drive Better Diabetes Treatment and Management

18-19 November 2014
London Marriott Hotel Marble Arch, United Kingdom

Why You Should Attend

Translating Innovations in Diabetes Drug Development

This conference will help delegates in developing safe and effective anti-diabetic pharmaceuticals - bringing together the key industry and academic experts in analysing cutting edge strategies on how to advance the latest anti-diabetic drugs. From pre-clinical testing through to clinical efficacy, this event will give the opportunity to discuss the key issues, while focusing on how to translate current and future innovations (from new molecular targets to regenerative medicines) into their pipeline for successful market access.

The global diabetes market is projected to double from $32bn to $64bn over the next 15 years as a result of changing demographics and new therapies entering the clinic. Now at epidemic levels, diabetes will affect eight percent of the world’s adult population by 2030. The industry is desperate to develop and embrace new innovations to develop a new pipeline in treating diabetes. Currently almost all treatment relies on insulin which has long been a treatment for diabetes, but they only help with the symptoms rather than cure the disease.


Key Topics

  • Regeneron on their regenerative progress and new found factors that increase beta-cell function
  • Novo Nordisk’s innovations in managing diabetes and insights in lifting research to the clinic
  • F. Hoffmann La Roche’s unique research and development on browning, oral peptides and compound screening
  • Boehringer Ingelheim’s experience from new cardiovascular testing in diabetes drug development
  • Sanofi’s pre-clinical progression on ceramide signalling and new drug targets
  • Previous Attendees Include

    Almirall, Amgen, AstraZeneca, Baxter, Genmab, La Roche, Merck
    Serono, Novartis, Pfizer ...and many more.

    Why Choose marcus evans?

    marcus evans specialises in the research and development of strategic events for senior business executives. From our international network of 63 offices, marcus evans produces over 1000 event days a year on strategic issues in corporate finance, telecommunications, technology, health, transportation, capital markets, human resources and business improvement.

    Above all, marcus evans provides clients with business information and knowledge which enables them to sustain a valuable competitive advantage and makes a positive contribution to their success.

    Event Partners

    Practical Insights From

    Tomas Landh
    Director, Strategy & Innovation Sourcing, Diabetes Research Unit
    Novo Nordisk

    Alexander Fleming
    Founder & Chief Medical Officer
    Exsulin Corporation & Former FDA

    Matthew Wright
    Expert Scientist & Research Leader
    F. Hoffmann La Roche

    Hans-Juergen Woerle
    Vice President, Therapeutic Area Head Metabolism, Corporate Division Medicine
    Boehringer Ingelheim

    Jesper Gromada
    Head, Metabolism & Muscle Therapeutic Areas
    Regeneron Pharmaceuticals

    Karin Conde-Knape
    Vice President Cardiovascular & Metabolism Scientific Innovation
    Johnson & Johnson Innovation Centre

    Prof Luigi Gnudi
    Professor of Diabetes & Metabolic Medicine Head, Unit for Metabolic Medicine, Cardiovascular Division
    King’s College London

    Click Here For Full Agenda

    Voice of Our Customers
    Join the Discussion

    Follow on LinkedIn

    Event Contact

    For all enquiries regarding speaking, sponsoring and attending this conference contact:

    Daniel Schuster

    PO Box 24797
    CY-1304 Nicosia

    +357 22 849 308
    Fax: +357 22 859 307